Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Ve...
Q1 2026
May 7, 2026
FY 2025
Mar 19, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 7, 2025